CTRI/2018/12/016757已完成4 期
European Prospective Registry on Sirolimus Drug-coated Balloon (thE All-comers Sirolimus-coaTed BallOon eURopeaN rEgistry: the EASTBOURNE REGISTRY). - EASTBOURNE
Fatebenefratelli and Ophthalmic Hospital0 个研究点目标入组 15 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1) Age >18 years.
- •2) Patients with symptomatic coronary artery disease (including patients
- •with chronic stable angina, silent ischemia, and acute coronary
- •syndromes) with clinical indication to PCI.
- •3) Informed consent for the study
排除标准
- •1) Patients participating in another clinical evaluation;
- •2) Every known allergy, intolerance or hypersensitivity to any medication used
- •during the procedure;
- •3) Target lesion severely calcific;
- •4) Target vessel severely tortuous.
- •5) preâ??dilatation not performed or unsuccessful (residual stenosis >50%);
- •6) Visible thrombus at lesion which is not treatable with aspiration
研究者
相似试验
招募中
Unknown
Clinical Research on Sirolimus Data Repositoryymphangioleiomyomatosis, Refractory Lymphatic DisordersJPRN-UMIN000051200iigata University
已完成
3 期
The Study of the BX VELOCITY Stent In Patients With De Novo Coronary Artery Lesions.Coronary Artery DiseaseNCT00235144Cordis Corporation353
已完成
3 期
An open-label continuation trial of sirolimus for tocilizumab-refractory idiopathic multicentric Castleman's disease: Study protocol for an investigator-initiated, multicenter, open-label trial (SPIRIT Compliant)JPRN-jRCT2051200050Kawakami Atsushi20
终止
1 期
Treating Multiple Sclerosis With Sirolimus, an Immune System SuppressorMultiple Sclerosis (MS) - Relapsing-remittingNCT00095329National Institute of Allergy and Infectious Diseases (NIAID)14
进行中（未招募）
1 期
on-randomised Open Label Pilot Study of Sirolimus Therapy for Segmental Overgrowth Due to PIK3CA- Related OvergrowthEUCTR2014-005320-10-FRCHU de DIJO